You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Pre-Diabetes Articles
Popular Pre-Diabetes Articles
Highly Recommended Pre-Diabetes Articles
Send a link to this page to your friends and colleagues.
This press release is an announcement submitted by American Diabetes Association, and was not written by Diabetes Health.
ALEXANDRIA, VA, Sep 01, 2009 (MARKETWIRE via COMTEX) - The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award.
The $1.2 million grant supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease. Each researcher will receive $600,000 to study the role of GLP-1 in people at risk for or with diabetes. GLP-1 is a hormone, secreted by L-cells located in the distal intestines, that stimulates insulin secretion in a glucose-dependent fashion.
Dr. Liu's research will help elucidate the role of native GLP-1 in the progression of obesity, pre-diabetes, and type 2 diabetes. The findings from this research could provide more insight into biomarkers that might be used to allow earlier intervention to prevent and/or treat obesity and/or pre-diabetes before type 2 diabetes develops.
Dr. Reaven's research will look beyond the direct effects of liraglutide, a GLP-1 analog, on glucose control, going on to explore areas such as weight control, satiety, and the effects on cardiovascular risk factors such as triglycerides and blood pressure.
"Studying the role of GLP-1 and other incretin hormones in people with type 2 diabetes and those at risk holds much promise," commented Scott Campbell, PhD, the American Diabetes Association Vice President of Research Programs. "Emerging science shows us that GLP-1 treatments can positively affect glucose metabolism and may increase beta cell mass, two important elements that could some day lead to a cure for type 2 diabetes."
"Novo Nordisk's highest priority has always been the health and well-being of people living with diabetes, and we strive to do everything we can to conduct and support research that will lead to the discovery of new, innovative treatments for people affected," said Nathaniel G. Clark, MD, MS, RD, Novo Nordisk's Senior Medical Advisor - Diabetes. "This is why, as part of our Changing Diabetes Leadership Initiative, we are truly pleased to support the American Diabetes Association in supporting studies investigating the full potential of this medication class in both those with and those at risk for type 2 diabetes."
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.